NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapiesElena Ardini, Marina Ciomei, Nilla Avanzi et al.|European Journal of Cancer|2016Cited by 1
Abstract 3795: Novel and selective MELK kinase inhibitors active in breast cancer cell linesPatrizia Carpinelli, Alessia Montagnoli, Marisa Montemartini et al.|Cancer Research|2016Cited by 0